胚胎著床前診斷(PGD)的全球市場:各類型，各終端用戶，各地區 - 規模，佔有率，展望，機會分析(2022年～2028年)

Preimplantation Genetic Diagnosis Market, By Type, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年05月08日 | 出版商:

Coherent Market Insights | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在胚胎著床前診斷(PGD)的全球市場中，移植用胚無法利用，是阻礙在預測期間內的成長的主要原因。

本報告提供全球胚胎著床前診斷(PGD)市場相關調查分析，推動市場要素與阻礙因素，市場機會，COVID-19影響，各類型、終端用戶、地區的市場分析，競爭情形等資訊。

Preimplantation genetic diagnosis (PGD) is the genetic profiling of the pre implantable embryos and oocytes before their implantation. The preimplantation genetic diagnosis is similar to that of the parental diagnosis in case of screening for a particular genetic disease. The PGD is advantageous in a way that helps to avoid selective pregnancy termination by the development and growth of the healthy fetus. PGD serves as an addendum to assisted reproductive technology. The preimplantation genetic diagnosis is required in vitro fertilization, in order to obtain oocytes from the embryos for the genetic evaluation of the diseased or disease-free conditions. In simpler terms, the preimplantation genetic diagnosis is a technique that is used to identify embryos at risk.

Restraints of the Global Preimplantation Genetic Diagnosis Market

Major factors hampering the growth of the preimplantation genetic diagnosis market during the forecast period constitutes of non-availability of embryos for transfer.

Key features of the study:

This report provides in-depth analysis of the global preimplantation genetic diagnosis market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

It profiles leading players in the global preimplantation genetic diagnosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans

Key companies covered as a part of this study include Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.

Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics

The global preimplantation genetic diagnosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

Global Preimplantation Genetic Diagnosis Market, By Type:
- Chromosomal Abnormalities
- Aneuploidy
- X-linked diseases
- Single gene disorders
- HLA Typing
- Gender Selection
- Others (for disability, adult onset disease)
Global Preimplantation Genetic Diagnosis Market, By End User:
- Diagnostic Laboratories
- Hospitals
- Clinics
Global Preimplantation Genetic Diagnosis Market, By Geography:
- North America
By Type
- Chromosomal Abnormalities
- Aneuploidy
- X-linked diseases
- Single gene disorders
- HLA Typing
- Gender Selection
- Others (for disability, adult onset disease)
By End User
- Diagnostic Laboratories
- Hospitals
- Clinics
By Country:
- U.S.
- Canada
- Europe
By Type
- Chromosomal Abnormalities
- Aneuploidy
- X-linked diseases
- Single gene disorders
- HLA Typing
- Gender Selection
- Others (for disability, adult onset disease)
By End User
- Diagnostic Laboratories
- Hospitals
- Clinics
By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
By Type
- Chromosomal Abnormalities
- Aneuploidy
- X-linked diseases
- Single gene disorders
- HLA Typing
- Gender Selection
- Others (for disability, adult onset disease)
By End User
- Diagnostic Laboratories
- Hospitals
- Clinics
By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
By Type
- Chromosomal Abnormalities
- Aneuploidy
- X-linked diseases
- Single gene disorders
- HLA Typing
- Gender Selection
- Others (for disability, adult onset disease)
By End User
- Diagnostic Laboratories
- Hospitals
- Clinics
By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East:
By Type
- Chromosomal Abnormalities
- Aneuploidy
- X-linked diseases
- Single gene disorders
- HLA Typing
- Gender Selection
- Others (for disability, adult onset disease)
By End User
- Diagnostic Laboratories
- Hospitals
- Clinics
By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
By Type
- Chromosomal Abnormalities
- Aneuploidy
- X-linked diseases
- Single gene disorders
- HLA Typing
- Gender Selection
- Others (for disability, adult onset disease)
By End User
- Diagnostic Laboratories
- Hospitals
- Clinics
By Country/Region:
- Central Africa
- South Africa
- North Africa
Company Profiles
- Amgen Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
- Quest Diagnostics
- Vertex
- PerkinElmer, Inc.
- F. Hoffman-La-Roche Ltd
- Thermo Fisher Scientific, Inc.
- Laboratory Corporation of America Holdings
- Abbott Laboratories
- Illumina, Inc.
- Natera Inc.
- CooperGenomics Inc.
- Reproductive Genetics Institute, Inc.
- Genea Ltd.
- Invitae Corporation
- CombiMatrix Corporation

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By End User
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Developments
Regulatory Scenario
PEST Analysis
COVID-19 Impact Analysis

4. Global Preimplantation Genetic Diagnosis Market, By Type, 2017 - 2028 (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Chromosomal Abnormalities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
Aneuploidy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
X-linked diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
Single gene disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
HLA Typing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
Gender Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
Others (for disability, adult onset disease)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends

5. Global Preimplantation Genetic Diagnosis Market, By End User, 2017 - 2028 (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Preimplantation Genetic Diagnosis Market, By Regions, 2017 - 2028 (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
- Amgen Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Quest Diagnostics
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Vertex
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- PerkinElmer, Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- F. Hoffman-La-Roche Ltd
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Thermo Fisher Scientific, Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Laboratory Corporation of America Holdings
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Abbott Laboratories
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Illumina, Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Natera Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- CooperGenomics Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Reproductive Genetics Institute, Inc.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Genea Ltd.
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Invitae Corporation
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- CombiMatrix Corporation
  - Company Overview
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies